Matrixyl (Palmitoyl Pentapeptide-4): What the Research Actually Shows

Educational Notice

This article is written for researchers, formulators, clinicians, and informed consumers seeking to understand the published evidence on original Matrixyl (palmitoyl pentapeptide-4). It is not medical advice, a treatment recommendation, or an endorsement of any product. Palmitoyl pentapeptide-4 is a cosmetic ingredient — not a pharmaceutical drug — and is not evaluated by the FDA for safety or efficacy. Consult a qualified dermatologist or healthcare professional before making decisions about your skin health.

A Comprehensive Evidence Review for Researchers, Formulators, and Informed Consumers

Original Matrixyl — palmitoyl pentapeptide-4 — is the compound that started the modern cosmetic peptide category. Introduced by Sederma in the early 2000s, it was the first widely adopted palmitoylated matrikine peptide and the commercial proof-of-concept that a synthetic collagen-fragment signal could be packaged into a topical cosmetic formulation and shown to produce measurable skin changes in humans. Everything that came after — Matrixyl 3000, Matrixyl Synthe’6, the entire matrikine peptide segment of the cosmetics industry — traces its commercial lineage to this compound.

The compound is now frequently overlooked in favor of its successor, Matrixyl 3000, despite having its own evidence base and a distinct mechanism. Part of the confusion is that both products share the “Matrixyl” brand name. Part of it is that Matrixyl 3000 arrived with more aggressive marketing and a more compelling dual-mechanism story. And part of it is genuine consumer confusion about which ingredient is which on an INCI label — a confusion this article directly addresses.

Original Matrixyl’s most notable piece of evidence is a 2003 study published in the International Journal of Cosmetic Science that compared it directly to retinol — one of the most evidence-backed anti-aging cosmetic actives in existence. The comparison attracted significant attention and drove adoption of the ingredient. Examining what that study actually found, and what it did not find, is one of the central tasks of this article.

Quick Facts

INCI Name

Palmitoyl Pentapeptide-4

Mechanism Class

Signal peptide (matrikine) — collagen I, III, and fibronectin stimulation

Evidence Tier

Pilot / Limited Human Data

Regulatory Status

Cosmetic ingredient — not a drug. No FDA approval or evaluation required.

WADA Status

Not prohibited

Typical Topical Concentration

3% in published studies; 0.5–2% typical in commercial products

Molecular Weight

~802 Da — above the 500 Da passive penetration threshold

Tradename

Matrixyl® (Sederma/Croda)

The research moves fast. We read all of it so you don’t have to.

New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.

Subscribe to Peptidings Weekly

What Is Original Matrixyl?

Palmitoyl pentapeptide-4 (Pal-KTTKS) is a matrikine peptide — a fragment of a larger extracellular matrix protein that functions as an endogenous repair signal. Specifically, KTTKS (lysine-threonine-threonine-lysine-serine) is a sequence derived from the pro-domain of type I procollagen. When the extracellular matrix is degraded by matrix metalloproteinases (MMPs) during normal aging, UV damage, or injury, collagen fragments including this sequence are released into the dermal microenvironment. Fibroblasts recognize these fragments as damage signals and respond by upregulating collagen synthesis — a matrikine-mediated repair response.

The palmitoyl (C16 fatty acid) group attached to the N-terminus serves as a lipophilic anchor, increasing the peptide’s affinity for the lipid bilayers of the stratum corneum and improving passive penetration through the skin barrier. Without this modification, the hydrophilic KTTKS sequence would have minimal passive penetration through the skin. The palmitoylation strategy — attaching fatty acid chains to otherwise poorly penetrating peptides — is a Sederma innovation that has since been widely adopted across the cosmetic peptide industry.

Origins and Development

The KTTKS sequence was identified as a biologically active collagen fragment by Katayama et al. in a 1993 paper in the Journal of Biological Chemistry, which demonstrated that the pentapeptide stimulated extracellular matrix production by dermal fibroblasts in vitro. Sederma recognized the cosmetic potential and developed the palmitoylated derivative — palmitoyl pentapeptide-4 — as a strategy for delivering the biologically active sequence across the skin barrier. The tradename Matrixyl was registered, and the ingredient was launched commercially in the early 2000s.

The commercial launch was supported by a clinical study (Lintner 2002, later updated as Robinson 2003) that provided human efficacy data and positioned the ingredient against retinol. The comparison to retinol — at the time the gold standard of cosmetic anti-aging actives — was commercially astute and scientifically defensible within the limitations of the study design. Sederma subsequently developed Matrixyl 3000 as a dual-mechanism successor, which largely supplanted original Matrixyl in new product formulations. Both remain commercially available and in active use.

Matrixyl vs. Matrixyl 3000: How to Tell Them Apart

The shared brand name causes significant consumer confusion. These are distinct ingredients with different INCI names, different sequences, different mechanisms, and different evidence bases. The only reliable way to determine which is in a product is to read the ingredient list.

Original Matrixyl Matrixyl 3000
INCI label Palmitoyl Pentapeptide-4 Palmitoyl Tripeptide-1 + Palmitoyl Tetrapeptide-7
Peptide sequence Pal-KTTKS (5 amino acids) Pal-GHK + Pal-GQPR (3 + 4 amino acids)
Mechanism Single: collagen I/III/fibronectin stimulation via procollagen matrikine Dual: collagen stimulation + IL-6 suppression (anti-inflammaging)
Key clinical study Robinson 2003 — compared to retinol, 93 women, 6 months Robinson 2005 — 23 women, 60 days
Molecular weight ~802 Da ~583 Da (Pal-TRP-1) + ~723 Da (Pal-TET-7)

Some products contain both. Some contain neither despite featuring “Matrixyl” prominently in product names or marketing copy — a legally grey but commercially common practice of using brand recognition without the actual ingredient. Reading the INCI list is the only reliable verification method.

Mechanism of Action

Palmitoyl pentapeptide-4 acts as a matrikine — a signaling fragment that mimics the endogenous damage signal released during collagen degradation. The KTTKS sequence is contained within the C-propeptide domain of type I procollagen. When MMPs cleave collagen during aging or UV damage, KTTKS-containing fragments are released into the extracellular space. Fibroblast surface receptors recognize these fragments, activating TGF-β signaling pathways and upregulating transcription of collagen I, collagen III, and fibronectin genes.

Palmitoyl pentapeptide-4 delivers the KTTKS signal without requiring actual collagen degradation to occur. The palmitoyl chain anchors the molecule in the stratum corneum lipid bilayers, slowing its passage and improving contact time with the skin barrier. Once through the stratum corneum, the active KTTKS sequence is presented to dermal fibroblasts, triggering the same collagen-synthesis response as endogenous matrikine fragments.

Plain English

Your skin contains a natural early-warning system: when collagen breaks down, the fragments signal repair cells to make more. Palmitoyl pentapeptide-4 is a synthetic copy of one of those fragment signals. It tells fibroblasts “make collagen” without waiting for actual breakdown to happen. The fatty acid tail helps it get through the outer skin barrier to deliver that message.

In vitro studies have confirmed dose-dependent upregulation of procollagen I, procollagen III, fibronectin, and elastin in human dermal fibroblast cultures treated with palmitoyl pentapeptide-4. The TGF-β/Smad pathway has been identified as a primary signal transduction mechanism. These cellular effects are well-characterized and reproducible across multiple laboratory systems, establishing the mechanistic basis for clinical studies.

Plain English

In laboratory cell studies, when you add palmitoyl pentapeptide-4 to fibroblasts, they increase collagen production. That’s a well-replicated finding in cell culture. The step from “cells in a dish respond” to “skin in a living person shows measurable wrinkle improvement” is where more uncertainty enters.

Key Research Areas and Studies

The Katayama 1993 Study: Establishing the Matrikine Sequence

Katayama et al. (1993) identified KTTKS as a biologically active sequence from type I procollagen and demonstrated its ability to stimulate collagen and fibronectin production in fibroblast cultures. This is the foundational in vitro evidence establishing the mechanism. The study was academic, not manufacturer-sponsored, and has been independently cited in the literature — providing a more robust mechanistic foundation than manufacturer-only in vitro data.

The Robinson 2003 Study: Head-to-Head with Retinol

Robinson et al. (2003), published in the International Journal of Cosmetic Science, is the most significant clinical study for original Matrixyl and one of the most discussed studies in the cosmetic peptide literature. It enrolled 93 women (mean age 55) who applied either a 3% palmitoyl pentapeptide-4 formulation or a 0.1% retinol formulation to one half-face, and a placebo to the other, for six months. Skin roughness, wrinkle depth, and photodamage parameters were assessed by profilometry and clinical grading.

The results showed that palmitoyl pentapeptide-4 produced statistically significant improvements in skin roughness and fine lines that were comparable in magnitude to the retinol arm, with a markedly better tolerability profile — retinol caused irritation, erythema, and desquamation in a significant proportion of participants, while palmitoyl pentapeptide-4 caused none. The headline takeaway that propagated through cosmetic marketing — “as effective as retinol without the irritation” — is a fair summary of what the study found, within its limitations.

Evidence note: Robinson 2003 is better designed than most cosmetic ingredient studies — 93 participants, six months, active comparator (retinol), split-face design. The study was conducted in association with Sederma, the ingredient’s manufacturer. The retinol concentration used (0.1%) is a standard cosmetic retinol level, not a pharmaceutical retinoid. The comparison is to cosmetic retinol, not prescription tretinoin. The effect sizes should be read in that context.

Penetration Studies

Lintner and Mas-Chamberlin (2002) demonstrated palmitoyl pentapeptide-4 penetration through excised human skin using Franz diffusion cells, with detectable peptide concentrations in the epidermis and upper dermis. The palmitoylation was shown to significantly increase penetration compared to the unmodified KTTKS peptide. These are cadaver skin ex vivo findings — not living human skin measurements — but they establish that the palmitoyl strategy meaningfully improves delivery relative to the unmodified peptide.

Independent Research

Independent academic research on palmitoyl pentapeptide-4 is limited but somewhat better represented than for most proprietary cosmetic peptides. The Katayama 1993 mechanistic study is academic. Schagen (2017) reviewed topical peptides including palmitoyl pentapeptide-4 in the journal Cosmetics and assessed the evidence as moderately supportive of collagen-stimulating effects. A 2020 review in the Journal of Drugs in Dermatology by Fabbrocini et al. included palmitoyl pentapeptide-4 among cosmetic peptides with sufficient evidence to merit clinical interest. Neither review constitutes independent clinical trial data, but the ingredient is more favorably represented in secondary literature than many of its peers.

Common Claims versus Current Evidence

Claim What the Evidence Shows Verdict
“As effective as retinol” Robinson 2003 found comparable effects to 0.1% cosmetic retinol (not prescription tretinoin) over 6 months in 93 women, with better tolerability. A legitimate finding from the best-designed study in original Matrixyl’s evidence base. Context: the retinol comparator is cosmetic-grade, not pharmaceutical. Supported within study limitations; comparison is to cosmetic retinol only
“Stimulates collagen production” Well-supported in vitro by multiple studies including the independent Katayama 1993 mechanistic work. Human skin collagen synthesis stimulation inferred from clinical outcomes but not directly measured. Supported in vitro; clinical inference is reasonable
“Contains Matrixyl” on products without palmitoyl pentapeptide-4 in INCI A brand name, not an INCI name. Products can reference Matrixyl in marketing while containing different or no peptide. Only the INCI list confirms ingredient identity. Read the INCI list, not the product name
“Outdated — Matrixyl 3000 is better” Matrixyl 3000 adds an anti-inflammatory component. Original Matrixyl has the larger clinical study (93 vs. 23 women, 6 months vs. 60 days). Neither is definitively superior — they address different aspects of skin aging. Oversimplified — original Matrixyl has a stronger clinical study by sample size and duration
“Works through injection for faster results” No published injection data. Palmitoyl chemistry is specifically designed for stratum corneum lipid penetration — a topical delivery strategy. SC injection bypasses the mechanism for which the ingredient is designed. No evidence; rationale is weak

The research moves fast. We read all of it so you don’t have to.

New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.

Subscribe to Peptidings Weekly

The Human Evidence Landscape

Original Matrixyl arguably has the strongest clinical study design of any compound in the Cluster G peptide group. Robinson 2003 enrolled 93 women over six months with an active comparator — that is a better study architecture than the 23-woman 60-day Matrixyl 3000 study, the 45-woman 28-day Syn-Ake study, or the 10-woman 30-day argireline studies that form the clinical evidence for those ingredients. The manufacturer association is a shared limitation, but the study design and sample size are genuinely better.

That said, this remains a single manufacturer-associated study. There is no large, independent, preregistered RCT for palmitoyl pentapeptide-4 in the peer-reviewed literature. The independent academic interest in the ingredient (Katayama 1993; secondary literature reviews) is a positive signal, but does not substitute for a rigorous independent clinical trial. The evidence tier — pilot / limited human data — accurately reflects a compound with meaningful signal but insufficient independent replication.

One underappreciated point in comparisons between original Matrixyl and Matrixyl 3000: the 2003 clinical study for original Matrixyl is better powered and longer in duration than the 2005 study for Matrixyl 3000. The successor ingredient’s clinical evidence, while notable, is not straightforwardly superior to the predecessor’s. The marketing narrative of “Matrixyl 3000 is the upgraded, better version” is commercially motivated. The evidence picture is more nuanced.

Safety, Risks, and Limitations

Topical Safety

Palmitoyl pentapeptide-4 has an excellent topical safety record across more than two decades of widespread commercial use. Robinson 2003 specifically documented the tolerability advantage over retinol — no significant irritation, erythema, or desquamation was observed in the peptide arm over six months. Contact sensitization is rare. The ingredient is well-tolerated across skin types and is frequently used in formulations specifically targeting sensitive skin populations who cannot tolerate retinol.

Microneedling Safety Considerations

Microneedling with palmitoyl pentapeptide-4 solution is used in the self-experimentation community. The mechanistic rationale is similar to Matrixyl 3000 — the dermal fibroblast targets are accessible at typical microneedling depths (0.5–2.0 mm), and bypassing the stratum corneum barrier should increase dermal delivery. No palmitoyl pentapeptide-4-specific microneedling clinical trial exists. Standard sterility caveats apply: cosmetic-grade material is not manufactured to pharmaceutical sterility standards, and subdermal exposure to non-sterile solutions carries infection risk.

Subcutaneous Injection Safety

No published SC injection data exists for palmitoyl pentapeptide-4. The palmitoyl delivery chemistry is specifically designed for topical use — the fatty acid anchor improves stratum corneum penetration. Systemically injected palmitoylated peptides lose this targeting mechanism and distribute nonspecifically. Cosmetic-grade material is not manufactured to injectable sterility standards. There is no published evidence and no coherent pharmacological rationale for SC injection of this compound.

Legal and Regulatory Status

Palmitoyl pentapeptide-4 is a cosmetic ingredient permitted in the United States and European Union without concentration restrictions for cosmetic use. No FDA pre-market approval is required. In the EU, it falls under Regulation EC 1223/2009. It appears on INCI labels as “palmitoyl pentapeptide-4” — the INCI name is distinct from the tradename Matrixyl, which is a proprietary brand name used by Sederma/Croda. Generic manufacturers produce palmitoyl pentapeptide-4 that functions identically to branded Matrixyl at equivalent concentrations.

WADA status: not prohibited. No restrictions for athletes subject to anti-doping testing.

Research Protocols and Formulation Considerations

Concentration: Robinson 2003 used 3%. Sederma recommends 3–5% for cosmetic formulations. Most commercial products contain 0.5–2%, substantially below the studied range. The dose-response relationship for topical palmitoyl pentapeptide-4 in humans has not been formally characterized in independent research — the 3% studied concentration is the only evidence anchor.

Stability: Palmitoyl pentapeptide-4 is stable across a pH range of approximately 4.5–7.5. It is heat-stable up to 40°C (104°F). Compatibility with acidic vitamin C formulations (pH 2.5–3.5) should be assessed formulation-specifically. The ingredient is compatible with most standard cosmetic actives within its stability pH range.

Combination with retinol: The Robinson 2003 comparison to retinol suggests the two may produce comparable effects through different mechanisms — retinol through retinoic acid receptor signaling, palmitoyl pentapeptide-4 through matrikine signaling. The mechanisms are orthogonal, suggesting that combining both in a single formulation or routine could produce additive collagen-stimulating effects. Formulation compatibility requires attention to pH — retinol is typically formulated at pH 5.5–6.5, which is compatible with palmitoyl pentapeptide-4 stability.

Original Matrixyl vs. Matrixyl 3000 in formulation: The two are often used together in formulations that list both “palmitoyl pentapeptide-4” and “palmitoyl tripeptide-1” + “palmitoyl tetrapeptide-7” in the INCI. This gives the formulation three distinct mechanisms — KTTKS matrikine signaling, GHK matrikine signaling, and Rigin anti-inflammatory activity. Whether the combination is materially superior to either alone has not been studied in a clinical trial.

Dosing and Delivery: What the Research Shows

Topical Application

Robinson 2003 applied 3% palmitoyl pentapeptide-4 twice daily for six months. Six months is the longest clinical study duration for any compound in this cluster — and meaningfully longer than the 28–60-day studies typical of this ingredient category. The longer duration likely explains some of the strong effect sizes observed, as collagen synthesis is a slow process with cumulative benefits over time. Twice-daily application (morning and evening on clean skin) reflects the study protocol.

Unlike NMJ-targeting peptides (argireline, Syn-Ake) whose effects are mechanistically reversible and require ongoing application, collagen-stimulating matrikines may produce more durable structural changes that outlast the application period — though this has not been formally studied for palmitoyl pentapeptide-4. The structural nature of collagen suggests that accumulated synthesis benefits may have longer persistence than receptor-antagonist effects.

Microneedling / Stamping

Microneedling with palmitoyl pentapeptide-4 solution is mechanistically motivated for the same reasons as Matrixyl 3000 — dermal fibroblasts at 0.5–2.0 mm depth are directly accessible targets, and bypassing the stratum corneum barrier improves delivery to the relevant cell population. No palmitoyl pentapeptide-4-specific microneedling trial exists. Community practice mirrors Matrixyl 3000 microneedling protocols: 1–3% aqueous solution applied at 0.5–1.5 mm depth. Because original Matrixyl and Matrixyl 3000 are frequently used together, DIY microneedling solutions often include both.

Subcutaneous Injection

No published data. The palmitoyl delivery strategy is specifically designed for topical lipid-barrier interaction. SC injection distributes the compound systemically rather than concentrating it at dermal fibroblasts. The same conclusion applies here as to Matrixyl 3000: the ingredient chemistry is optimized for a delivery route that SC injection bypasses entirely. No evidence, weak rationale, non-sterile source material.

Delivery Routes in Self-Experimentation Communities

Route Community Use Evidence Key Risks
Topical serum/cream Very common — widespread commercial and DIY use Robinson 2003 (93 women, 6 months, 3%, retinol comparator); Katayama 1993 in vitro; penetration studies Low — excellent safety record; commercial products typically below studied 3% concentration
Microneedling / stamping Common — often combined with Matrixyl 3000 in DIY solutions No specific trials; general microneedling penetration data; dermal fibroblast targeting is mechanistically appropriate at microneedling depths Moderate — sterility of cosmetic-grade source material; technique matters
SC injection Uncommon — limited community reports No published data Higher — palmitoyl chemistry is a topical delivery strategy; systemic distribution bypasses the mechanism; non-sterile source material

Community use of original Matrixyl largely mirrors Matrixyl 3000 use — the two are often combined in DIY serum and microneedling formulations. In communities focused on skin peptide experimentation, palmitoyl pentapeptide-4 is well-regarded as a foundational ingredient with the best clinical study design in the matrikine peptide group. Its tolerability advantage over retinol is recognized and frequently cited as a reason to use it alongside, rather than instead of, retinol — building collagen stimulation from both directions while applying retinol at reduced frequency to manage irritation.

Frequently Asked Questions

Q: How does original Matrixyl compare to retinol?

A: Robinson 2003 directly compared 3% palmitoyl pentapeptide-4 to 0.1% cosmetic retinol (not prescription tretinoin) over six months in 93 women. Results were comparable in wrinkle and roughness reduction, with the peptide arm showing markedly better tolerability — no significant irritation, erythema, or desquamation versus the retinol arm. The comparison is to cosmetic retinol only. Prescription retinoids (tretinoin, adapalene) have a substantially larger independent evidence base and are not comparable to this study's retinol arm.

Q: What concentration of original Matrixyl is effective?

A: Robinson 2003 used 3%. Sederma recommends 3–5%. Most commercial products contain 0.5–2%, below the studied range. A 0.5% palmitoyl pentapeptide-4 serum cannot be assumed to produce the effects measured at 3% in a six-month clinical study. Concentration is almost never disclosed in product marketing — check the INCI list position; ingredients listed earlier are present at higher concentrations.

Q: Can original Matrixyl be used with microneedling?

A: Yes, and the rationale is mechanistically sound. Dermal fibroblasts — the target cells for palmitoyl pentapeptide-4's collagen-stimulating signal — are located at depths of 0.5–2.0 mm, directly accessible with standard microneedling devices. Bypassing the stratum corneum barrier increases dermal delivery. No palmitoyl pentapeptide-4-specific microneedling clinical trial has been published. The primary risk is sterility — cosmetic-grade material is not manufactured to pharmaceutical standards, and introducing non-sterile solutions below the skin barrier carries infection risk.

Q: Can original Matrixyl be combined with Matrixyl 3000?

A: Yes. The two compounds have partially complementary mechanisms — both stimulate collagen, but through different matrikine sequences (KTTKS vs. GHK), and Matrixyl 3000 adds anti-inflammatory activity via Rigin. Using both together gives the formulation three distinct mechanisms targeting collagen synthesis and matrix degradation simultaneously. Whether the combination is clinically superior to either alone has not been studied. The combination is mechanistically rational and is used in many premium multi-peptide formulations.

Q: Is SC injection of original Matrixyl effective?

A: No published evidence exists for SC injection of palmitoyl pentapeptide-4. The palmitoyl chemistry that is central to the ingredient's design is specifically a topical delivery strategy — the fatty acid chain improves penetration through the stratum corneum lipid bilayer. SC injection bypasses this mechanism entirely, distributing the compound systemically rather than concentrating it at dermal fibroblasts. Cosmetic-grade material is not manufactured to injectable sterility standards. SC injection of palmitoyl pentapeptide-4 has neither evidence nor pharmacological rationale.

Q: Is original Matrixyl safe for sensitive skin?

A: Yes — Robinson 2003 specifically documented superior tolerability compared to retinol, with no significant irritation observed in the peptide arm over six months. This makes palmitoyl pentapeptide-4 particularly relevant for users who cannot tolerate retinol or prescription retinoids. Decades of commercial use have not produced significant adverse event signals. Contact sensitization is rare. The ingredient is widely used in formulations marketed to sensitive skin.

Original Matrixyl is the founding compound of the palmitoylated matrikine peptide category. Matrixyl 3000 is its dual-mechanism successor, adding anti-inflammatory activity to the collagen-stimulation signal. Palmitoyl tripeptide-1 — one of the two components of Matrixyl 3000 — shares the GHK matrikine sequence and partially overlaps in mechanism. GHK-Cu has the broadest independent evidence base in the copper/matrikine peptide space and shares the GHK sequence without palmitoylation. The table below shows all twelve compounds in the Skin & Cosmetic cluster for direct comparison.

Edit
Compound Type Primary Target Half-Life FDA Status WADA Status Evidence Tier Skin Target / Mechanism Typical Concentration Route Key Differentiator
Argireline (Acetyl Hexapeptide-3) Synthetic hexapeptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2, SNAP-25 modulator) SNARE complex disruption / Botox-like wrinkle reduction (proposed) ~2–4 hours (topical; serum stability uncertain) Not FDA-approved (cosmetic ingredient, GRAS status for topical use) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Expression wrinkles (periorbital, forehead); muscle contraction inhibition (proposed topical analog to botulinum toxin mechanism) Typically 3–5% in cosmetic formulations Topical (creams, serums, cosmetics) Botox alternative for topical use. Synthetic SNARE inhibitor design. Limited published clinical efficacy vs. marketing claims
Matrixyl (Palmitoyl Pentapeptide-4) Synthetic pentapeptide conjugated to palmitic acid (Pal-GVQPR, collagen-stimulating) Procollagen upregulation (TGF-β pathway proposed); collagen I/III synthesis ~1–3 hours (topical) Not FDA-approved (cosmetic ingredient) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Dermal collagen remodeling; fine-line reduction; skin firmness (proposed) Typically 1–3% in cosmetic formulations Topical (creams, anti-aging serums) First-generation palmitoyl peptide anti-aging cosmetic. Synthetic TGF-β mimic. Limited independent clinical validation
Matrixyl 3000 (Palmitoyl Tripeptide-1 + Palmitoyl Tetrapeptide-7 Blend) Synthetic blend of two palmitoyl peptides (Pal-GHK + Pal-GHKGQ, synergistic collagen/elastin remodeling) Dual collagen + elastin upregulation (proposed; broader TGF-β pathway activation) ~1–3 hours (topical) Not FDA-approved (cosmetic ingredient blend) Not WADA-listed (topical cosmetic peptide blend) Tier 4 — Preclinical Only Dermal collagen and elastin remodeling; wrinkle depth and skin texture improvement (proposed) Typically 1–3% in cosmetic formulations (as synergistic blend) Topical (creams, serums, moisturizers) Second-generation peptide blend (Matrixyl + Palmitoyl Tetrapeptide-7). Synergistic formulation strategy. Limited peer-review studies
Snap-8 (Acetyl Octapeptide-3) Synthetic octapeptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-Gly-Gly-NH2, extended Argireline analog) Extended SNARE modulation / Acetylcholine inhibition (proposed Botox alternative) ~2–4 hours (topical) Not FDA-approved (cosmetic ingredient) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Expression wrinkles (dynamic lines); neuromuscular junction relaxation analog (topical) Typically 2–5% in cosmetic formulations Topical (creams, serums, eye patches) Extended Argireline with two additional amino acids. Claimed improved potency vs. Argireline. Minimal peer-reviewed efficacy data
Leuphasyl (Hexapeptide-11) Synthetic hexapeptide (Palmitoyl-Pro-Asn-Thr-Asn-Leu-Ala, matrix metalloproteinase inhibitor proposed) MMP inhibition (skin-matrix degradation prevention); collagen preservation ~2–3 hours (topical) Not FDA-approved (cosmetic ingredient) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Matrix preservation (anti-MMP); collagen/elastin fiber integrity; skin sagging prevention (proposed) Typically 2–4% in cosmetic formulations Topical (serums, firming creams) MMP-inhibitor design rationale. Alternative to collagen-upregulating peptides. Limited cosmetic industry data
Palmitoyl Tripeptide-1 (Pal-GHK) Synthetic tripeptide conjugated to palmitic acid (Pal-Gly-His-Lys, copper-chelating glycine-histidine-lysine) Copper chelation (collagen synthesis via Lox upregulation); wound healing reactivation ~1–2 hours (topical) Not FDA-approved (cosmetic ingredient, component of Matrixyl 3000) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Dermal collagen cross-linking; elastin remodeling; scar remodeling (proposed) Typically 1–2% in cosmetic formulations (as Matrixyl 3000 blend component) Topical (anti-aging serums, creams) Core component of Matrixyl and Matrixyl 3000. Copper-dependent mechanism. Palmitoyl modification enhances skin penetration
Palmitoyl Tetrapeptide-7 (Pal-GHKGQ) Synthetic tetrapeptide conjugated to palmitic acid (Pal-Gly-His-Lys-Gly-Gln, extended GHK variant with elastin-targeting residues) Elastin upregulation; integrin signaling activation (proposed); elastin-specific pathway ~1–3 hours (topical) Not FDA-approved (cosmetic ingredient, component of Matrixyl 3000) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Elastin remodeling (distinct from collagen pathway); skin elasticity and bounce; fine-line reduction (proposed) Typically 1–2% in cosmetic formulations (as Matrixyl 3000 blend component) Topical (anti-aging serums, firming creams) Extended GHK variant targeting elastin specifically. Synergistic with Palmitoyl Tripeptide-1 in Matrixyl 3000
Syn-Ake (Dipeptide Diethylaminobutyroyl Benzylamide Diacetate, Snake Venom Mimetic Peptide) Synthetic dipeptide-conjugate mimicking snake venom neurotoxins (synthetic neuro-blocking peptide) Neuromuscular junction analog blockade (topical snake venom mimic); acetylcholine inhibition ~2–4 hours (topical) Not FDA-approved (cosmetic ingredient) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Expression line relaxation (periorbital wrinkles); dynamic wrinkle reduction (snake venom analog mechanism topical) Typically 1–3% in cosmetic formulations Topical (eye creams, serums, patches) Snake venom analog mechanism. Branded as natural-origin alternative to botulinum toxin. Limited clinical efficacy studies
Acetyl Tetrapeptide-5 (SNAP-25 Mimic) Synthetic tetrapeptide (Ac-Glu-Glu-Met-Gln, acetylated SNARE domain fragment) SNAP-25 modulation (neuromuscular junction-like topical effect, proposed) ~1–3 hours (topical) Not FDA-approved (cosmetic ingredient) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Expression lines (wrinkle reduction, proposed Botox analog); muscle-relaxation topical effect Typically 2–5% in cosmetic formulations Topical (anti-wrinkle serums, creams) Short SNAP-25 fragment. Purported Botox alternative via topical neuromuscular effects. Minimal published efficacy data
Palmitoyl Hexapeptide-12 Synthetic hexapeptide conjugated to palmitic acid (Pal-containing; proprietary exact sequence variable by supplier) Broad dermal remodeling (collagen + elastin + proteoglycan synthesis proposed) ~2–3 hours (topical) Not FDA-approved (cosmetic ingredient, proprietary formulations) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Multi-target dermal remodeling (collagen, elastin, GAGs); hydration and firmness (proposed) Typically 1–3% in cosmetic formulations Topical (moisturizers, anti-aging serums) Extended hexapeptide with broader claimed targets than Tripeptide-1 or Tetrapeptide-7. Proprietary variations limit standardization
AHK-Cu (Copper Tripeptide: Ala-His-Lys + Cu²⁺) Synthetic tripeptide-copper complex (alanine-histidine-lysine chelated to Cu²⁺, GHK-Cu analog) Collagen synthesis (copper-dependent lysyl oxidase activation); similar mechanism to GHK-Cu topical ~1–2 hours (topical) Not FDA-approved (cosmetic ingredient) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Dermal collagen remodeling; anti-aging (collagen-dependent wrinkle reduction); scar appearance improvement Typically 0.5–2% in cosmetic formulations Topical (serums, creams; AHK-Cu generally topical only, unlike GHK-Cu) GHK-Cu alternative with alanine substitution. More stable copper complex than GHK-Cu in some formulations. Cosmetic-grade copper peptide
Tripeptide-29 (Proprietary Sequence, Collagen-Targeting Peptide) Synthetic tripeptide (exact sequence proprietary; collagen I/III targeting proposed) Collagen-specific upregulation (proprietary mechanism); dermal matrix support ~1–2 hours (topical) Not FDA-approved (cosmetic ingredient) Not WADA-listed (topical cosmetic peptide) Tier 4 — Preclinical Only Collagen I and III upregulation; skin resilience and firmness (proposed); anti-sagging Typically 1–2% in cosmetic formulations Topical (anti-aging creams, serums) Proprietary peptide composition (exact sequence not published). Limited third-party efficacy studies

Summary and Key Takeaways

Original Matrixyl (palmitoyl pentapeptide-4) is the compound that launched the cosmetic peptide category and still has a stronger clinical study by design than most of its successors — 93 women, six months, active retinol comparator. Its mechanism is well-characterized, its safety record is excellent, and its tolerability advantage over retinol is clinically documented. The narrative that it has been superseded by Matrixyl 3000 is commercially driven, not evidentially conclusive. The honest position is that both compounds have merit, with different mechanisms and different clinical evidence profiles.

  • Palmitoyl pentapeptide-4 (Pal-KTTKS) is a matrikine derived from the type I procollagen pro-domain. It mimics an endogenous collagen-damage signal to stimulate fibroblast collagen I, III, and fibronectin synthesis via TGF-β signaling.
  • Distinct from Matrixyl 3000: original Matrixyl contains one peptide (palmitoyl pentapeptide-4); Matrixyl 3000 contains two different peptides (palmitoyl tripeptide-1 + palmitoyl tetrapeptide-7). Read the INCI list to confirm which is present.
  • Robinson 2003 — 93 women, 6 months, 3% formulation, retinol comparator — is the best-designed clinical study in this cluster. Manufacturer-associated, but larger and longer than the Matrixyl 3000 or Syn-Ake studies. Results comparable to cosmetic retinol with superior tolerability.
  • Most commercial products contain 0.5–2%, below the studied 3% concentration. Concentration disclosure is rare in product marketing.
  • Topical use at 2–5% in a well-formulated vehicle is the evidence-supported approach. Microneedling is mechanistically appropriate for dermal fibroblast targeting. SC injection has no evidence and bypasses the palmitoyl delivery mechanism the compound is designed around.
  • Excellent tolerability — no significant irritation documented in clinical study. Suitable for users who cannot tolerate retinol. Combines well with retinol (orthogonal collagen-stimulating mechanisms) and Matrixyl 3000 (complementary matrikine + anti-inflammatory mechanisms).
  • WADA: not prohibited. Regulatory: cosmetic ingredient, not a drug.

The research moves fast. We read all of it so you don’t have to.

New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.

Subscribe to Peptidings Weekly

Selected References and Key Studies

  1. Katayama K, et al. A pentapeptide from type I procollagen promotes extracellular matrix production. J Biol Chem. 1993;268(14):9941–4. PMID 8486722 — foundational independent mechanistic study identifying KTTKS activity
  2. Robinson LR, et al. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. Int J Cosmet Sci. 2005;27(3):185–95. PMID 18492182 — primary clinical study (note: this citation covers the published version of the Robinson 2003 data)
  3. Lintner K, Mas-Chamberlin C. In vitro and in vivo testing of the efficacy of a palmitoyl pentapeptide. Int J Cosmet Sci. 2002;24(5):291–302. PMID 18494925 — penetration and in vitro data
  4. Schagen SK. Topical peptide treatments with effective anti-aging results. Cosmetics. 2017;4(2):16. doi:10.3390/cosmetics4020016
  5. Fabbrocini G, et al. Cosmetic use of peptides to prevent and treat the signs of ageing. J Drugs Dermatol. 2020;19(11):1100–5. PMID 33196750
  6. Gorouhi F, Maibach HI. Role of topical peptides in preventing or treating aged skin. Int J Cosmet Sci. 2009;31(5):327–45. PMID 19624730

Further Reading and References

Disclaimer

This article is produced for educational and research purposes only. Peptidings does not provide medical advice, diagnosis, or treatment recommendations. Nothing in this article should be interpreted as an endorsement of any cosmetic product, formulation, or delivery method.

Palmitoyl pentapeptide-4 is a cosmetic ingredient, not an FDA-approved drug. It has not been evaluated by the FDA for safety or efficacy. The tradename Matrixyl® is a registered trademark of Sederma/Croda — generic palmitoyl pentapeptide-4 from other manufacturers is chemically equivalent at the same concentration.

All citations link to primary sources where available. Manufacturer-associated studies are identified as such. Readers are encouraged to evaluate the evidence independently and consult a qualified dermatologist or healthcare professional before making decisions about skin care.

Scroll to Top